Medicare beneficiaries with a body mass index of 35 or higher can now fill prescriptions for Wegovy and Zepbound at a flat $50 monthly copay, a price point that sits outside the standard Part D cost-sharing structure entirely. The Centers for Medicare and Medicaid Services activated the Medicare GLP-1 Bridge on July 1, 2026, creating a new access channel for weight-loss medications that were previously out of reach for most people on Medicare. The program runs through December 31, 2027, and the $50 payment does not count toward Part D deductibles or out-of-pocket maximums.
How the $50 flat copay changes drug access for BMI-35+ beneficiaries
For years, Medicare Part D plans excluded coverage of drugs prescribed purely for weight loss, a limitation reflected in current coverage rules that generally bar payment for medications used only to treat obesity. That changed when CMS structured the GLP-1 Bridge as a Section 402 demonstration, a legal mechanism that lets the agency test new payment and coverage models without full legislative action. The result is a fixed $50 copay for a one-month supply of eligible GLP-1 medications, available to Part D enrollees who meet the BMI threshold.
The flat-rate design matters because it removes the price uncertainty that has kept many patients from starting or staying on these drugs. Under commercial insurance, copays for Wegovy and Zepbound can swing from under $100 to well over $500 per month depending on plan design, formulary tier, and deductible status. A predictable $50 charge each month eliminates one of the biggest barriers to long-term use. If that consistency translates into higher 12-month persistence rates among Bridge enrollees compared with commercially insured patients facing variable copays, it would offer CMS strong evidence that cost predictability drives adherence in older adults with obesity.
The BMI cutoff of 35 qualifies a large share of the Medicare population. According to national statistics compiled by the National Institute of Diabetes and Digestive and Kidney Diseases, obesity rates among adults aged 60 and older have climbed steadily over the past two decades. Beneficiaries unsure of their BMI can use the calculator hosted by the National Heart, Lung, and Blood Institute to check their eligibility before contacting a prescriber. Clinicians are expected to confirm BMI and screen for contraindications before writing a Bridge-eligible prescription, but the threshold gives many older adults with severe obesity a clear path to qualify.
Clinical evidence and FDA approval behind Bridge drug selection
CMS did not pick Wegovy and Zepbound KwikPen at random. Wegovy, manufactured by Novo Nordisk, carries an FDA-approved indication for reducing the risk of serious heart problems in adults with obesity or overweight. The approval rested on trial data showing major adverse cardiovascular events occurred in 6.5% of patients treated with Wegovy versus 8.0% on placebo. That cardiovascular benefit gave CMS a clinical rationale to include the drug in a Medicare demonstration, since heart disease is the leading driver of costs and mortality in the over-65 population.
Zepbound, made by Eli Lilly, is a GLP-1/GIP agonist that has shown substantial weight-loss effects in clinical trials, including in adults with obesity and related metabolic risk factors. While its primary approval is for chronic weight management, CMS also weighed emerging evidence on improvements in blood pressure, glycemic control, and markers of cardiovascular risk. By limiting the Bridge to these two agents, the agency narrowed the demonstration to drugs with robust trial data in high-risk patients, rather than opening the door to every branded weight-loss product on the market.
Agency officials have also signaled that they are watching safety signals closely. GLP-1 drugs can cause gastrointestinal side effects and carry warnings about rare but serious risks such as pancreatitis. The Bridge requires standard FDA labeling to be followed, but CMS is layering on real-world monitoring, tracking discontinuation rates, adverse events, and hospitalizations among enrollees. Those data will help determine whether the cardiovascular and metabolic benefits observed in trials translate into measurable reductions in heart attacks, strokes, and other high-cost events for Medicare.
How pharmacies and plans are implementing the GLP-1 Bridge
The demonstration’s unusual financing structure places pharmacies at the center of execution. Under CMS guidance to participating pharmacies, claims for Wegovy and Zepbound dispensed under the Bridge are processed outside normal Part D benefit phases. Plans are required to accept the $50 copay at the point of sale, then reconcile the remainder of the drug cost through separate demonstration payment channels established by CMS.
For beneficiaries, the experience is designed to feel straightforward: once a prescriber submits a Bridge-eligible prescription and the plan confirms BMI-based eligibility, the pharmacy charges exactly $50 for a 30-day supply. That amount does not change during the demonstration period, regardless of whether a beneficiary has met their Part D deductible or entered the catastrophic coverage phase. Because the copay is carved out from standard benefit calculations, it also does not accelerate beneficiaries toward out-of-pocket thresholds.
Part D plans, meanwhile, must adapt their formularies, prior authorization workflows, and claims systems to flag Bridge-eligible fills. Some are creating dedicated “Bridge” indicators within their pharmacy benefit managers’ platforms to ensure that Wegovy and Zepbound prescriptions for qualifying patients route correctly. Others are training case managers to proactively identify high-BMI members who might benefit from the program, particularly those with a history of cardiovascular disease or diabetes.
Looking ahead, CMS has framed the Medicare GLP-1 Bridge as both an access initiative and a learning exercise. If the demonstration shows that a predictable $50 copay improves adherence, reduces cardiovascular events, and lowers total spending, it could inform permanent changes to how Medicare treats anti-obesity medications. For now, older adults with a BMI of 35 or higher have a time-limited opportunity to try two of the most powerful GLP-1 drugs on the market at a cost that is finally predictable – and, for many, finally affordable.
